

# Medical Policy



## Title: Testing Serum Vitamin D Levels

<b>Professional / Institutional</b>
Original Effective Date: August 26, 2009
Latest Review Date: January 23, 2024
Current Effective Date: February 25, 2022

**State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact [Blue Cross and Blue Shield of Kansas Customer Service](#).**

**The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.**

**The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.**

**If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.**

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> <li>Who are asymptomatic without conditions or risk factors for which vitamin D treatment is recommended</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Testing of vitamin D levels</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Routine care without testing vitamin D levels</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Overall survival</li> <li>Test validity</li> <li>Symptoms</li> <li>Morbid events</li> <li>Treatment-related morbidity</li> </ul>

**DESCRIPTION**

Vitamin D, also known as calciferol, is a fat-soluble vitamin that has a variety of physiologic effects, most prominently in calcium homeostasis and bone metabolism. In addition to the role it plays in bone metabolism, other physiologic effects include inhibition of smooth muscle proliferation, regulation of the renin-angiotensin system, a decrease in coagulation, and a decrease in inflammatory markers.

**OBJECTIVE**

The objective of this evidence review is to examine whether testing for vitamin D deficiency improves net health outcomes in asymptomatic individuals.

**BACKGROUND****Vitamin D**

Vitamin D, also known as calciferol, is a fat-soluble vitamin that has a variety of physiologic effects, most prominently in calcium homeostasis and bone metabolism. In addition to the role vitamin D plays in bone metabolism, other physiologic effects include inhibition of smooth muscle proliferation, regulation of the renin-angiotensin system, a decrease in coagulation, and a decrease in inflammatory markers.<sup>1</sup>

**Vitamin D Replacement**

The Institute of Medicine (now the National Academy of Medicine [NAM]) has recommended reference values for the intake of vitamin D and serum levels, based on available literature and expert consensus.<sup>2</sup> Recommended daily allowances are 600 IU/d for individuals between 1 and 70 years of age, and 800 IU/d for individuals older than 70 years.

Estimates of vitamin D requirements are complicated by the many other factors that affect serum levels. Sun exposure is the most prominent of factors that affect serum levels, and this is because individuals can meet their vitamin D needs entirely through adequate sun exposure. Other factors such as age, skin pigmentation, obesity, physical activity, and nutritional status also affect vitamin D levels and can result in variable dietary intake requirements to maintain adequate serum levels.

Excessive intake of vitamin D can be toxic. Toxic effects are usually due to hypercalcemia and may include confusion, weakness, polyuria, polydipsia, anorexia, and vomiting. In addition, high levels of vitamin D may promote calcium deposition and have the potential to exacerbate conditions such as calcium kidney stones and atherosclerotic vascular disease.

The Institute of Medicine defined 3 parameters of nutritional needs for vitamin D, on the assumption of minimal sun exposure. These parameters were the estimated average requirement, defined as the minimum intake required to maintain adequate levels; the recommended daily allowance, defined as the optimal dose for replacement therapy; and the upper-level intake, defined as the maximum daily dose to avoid toxicity. These recommendations are summarized in Table 1.

**Table 1. Institute of Medicine Recommendations for Vitamin D Dietary Intake**

<b>Patient Group</b>	<b>Estimated Average Requirement, IU/d</b>	<b>Recommended Daily Allowance, IU/d</b>	<b>Upper Limit Intake, IU/d</b>
1 to 3 years of age	400	600	2500
4 to 8 years of age	400	600	3000
9 to 70 years of age	400	600	4000
>70 years of age	400	800	4000

Adapted from Institute of Medicine (2011).<sup>2</sup>

### **REGULATORY STATUS**

The U.S. Food and Drug Administration (FDA) has cleared a number of immunoassays for in vitro diagnostic devices for the quantitative measurement of total 25-hydroxyvitamin D through the 510(k) process.

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Lab tests for vitamin D are available under the auspices of CLIA. Laboratories that offer laboratory-developed tests must be licensed by CLIA for high-complexity testing. To date, the FDA has chosen not to require any regulatory review of this test.

**POLICY**

- A. Testing for vitamin D deficiency may be considered **medically necessary** in individuals with signs and/or symptoms of vitamin D deficiency or toxicity (see Policy Guidelines) when one of the high-risk factors is present:
1. Chronic kidney disease, stage  $\geq 3$
  2. Granulomatous diseases
  3. Parathyroid disorders
  4. Cirrhosis and chronic liver disease
  5. Malabsorption states
  6. Chronic use of anticonvulsant medications or systemic corticosteroids
  7. Osteomalacia
  8. Osteopenia
  9. Osteoporosis
  10. Rickets
  11. Vitamin D deficiency, on replacement
  12. Hypo- or hypercalcemia
  13. Obstructive jaundice/biliary tract disease
  14. Osteogenesis imperfecta
  15. Osteosclerosis and osteopetrosis
- B. Testing vitamin D levels in asymptomatic individuals may be considered **medically necessary** in the following individual populations:
1. Individuals who have risk factors for vitamin D deficiency (as listed in Item A above)
  2. Institutionalized individuals (see Policy Guidelines)
- C. Testing vitamin D levels in asymptomatic individuals are considered **not medically necessary** when the above criteria are not met.
- D. Routine screening for vitamin D deficiency is **not medically necessary**.

**POLICY GUIDELINES**

- A. Signs and symptoms of vitamin D deficiency are largely manifested by changes in bone health and biochemical markers associated with bone production and resorption. In most cases, a clinical diagnosis of an abnormality in bone health (e.g., rickets, osteomalacia, osteoporosis) will lead to a decision to test vitamin D levels. Symptoms related to the clinical condition may be present (e.g., pain, low-impact fractures), but these symptoms are usually not indications for testing prior to a specific diagnosis. Some biochemical markers of bone health may indicate an increased risk for vitamin D deficiency, and testing of vitamin D levels may, therefore, be appropriate. These biochemical markers include unexplained abnormalities in serum calcium, phosphorus, alkaline phosphatase, and/or parathyroid hormone.
- B. Signs and symptoms of vitamin D toxicity (hypervitaminosis D) generally result from induced hypercalcemia. Acute intoxication can cause symptoms of confusion, anorexia, vomiting, weakness, polydipsia, and polyuria. Chronic intoxication can cause bone demineralization, kidney stones, and bone pain.

- C. “Institutionalized” as used herein refers to individuals who reside at long-term facilities where some degree of medical care is provided. These circumstances and facilities can include long-term hospital stays, nursing homes, assisted living facilities, and similar environments.
- D. The need for repeat testing may vary by condition. A single test may be indicated for diagnostic purposes; a repeat test may be appropriate to determine whether supplementation has been successful in restoring normal serum levels. More than 1 repeat test may be indicated occasionally, such as in cases where supplementation has not been successful in restoring levels (another example might include an instance in which continued or recurrent signs and symptoms may indicate ongoing deficiency, and/or when inadequate absorption or noncompliance with replacement therapy is suspected).

**Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

## **RATIONALE**

This evidence review has been updated regularly with searches of the PubMed database. The most recent literature update was performed through October 16, 2023.

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA (Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual); Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

## **Vitamin D Deficiency**

Vitamin D deficiency is best assessed by measuring serum levels of 25-hydroxyvitamin D. However, there is no consensus on the minimum vitamin D level or on the optimal serum level for overall health. A 2011 Institute of Medicine (IOM) report concluded that a serum level of 20 ng/mL is sufficient for most healthy adults.<sup>2</sup> Some experts, such as the Bone Health and

Osteoporosis Foundation (formerly the National Osteoporosis Foundation), have recommended a higher level (30 ng/mL) in some patient populations.<sup>3</sup>

Vitamin D deficiency, as defined by suboptimal serum levels, is common in the U.S. In the National Health and Nutrition Examination Survey covering the period of 2011 to 2014, 5% of patients aged 1 year and older were at risk of vitamin D deficiency (25-hydroxyvitamin D levels <12 ng/mL) and 18.3% of patients were at risk of vitamin D inadequacy (25-hydroxyvitamin D levels 12 to 19.6 ng/mL).<sup>4</sup> Vitamin D deficiency occurs most commonly as a result of inadequate dietary intake coupled with inadequate sun exposure. Evidence from the National Nutrition Monitoring System and the National Health and Nutrition Examination Survey has indicated that the average vitamin D consumption is below recommended levels of intake. Yetley (2008) estimated that the average daily intake for U.S. adults ranged from 228 to 335 IU/d, depending on gender and ethnicity.<sup>5</sup> This level is below the average daily requirement, estimated by IOM (400 IU/d for healthy adults), and well below IOM's required daily allowance (estimated to be 600 IU for nonelderly adults and 800 IU for elderly adults).

Vitamin D deficiency may occur less commonly for other reasons. Kidney or liver disease can cause deficiency as a result of the impaired conversion of inactive vitamin D to its active products. In rare situations, there is vitamin D resistance at the tissue level, which causes a functional vitamin D deficiency despite "adequate" serum levels.

The safe upper level for serum vitamin D is also not standardized. The IOM report concluded there is potential harm associated with levels greater than 50 ng/mL and recommended that serum levels be maintained in the 20 to 40 ng/mL range.<sup>2</sup> However, conclusions on this point have differed. A 2011 Agency for Healthcare Research and Quality systematic review of vitamin D and bone health concluded that "There is little evidence from existing trials that vitamin D above current reference intakes is harmful."<sup>6</sup> The Women's Health Initiative concluded that hypercalcemia and hypercalciuria in patients receiving calcium and vitamin D were not associated with adverse clinical events.<sup>7</sup> The Women's Health Initiative did find a small increase in kidney stones for women ages 50 to 79 years who received vitamin D and calcium.

Associations of vitamin D levels with various aspects of health have been noted over the last several decades,<sup>8,9,10,11,12</sup> and these findings have led to the question of whether supplementation improves health outcomes. For example, a relation between vitamin D levels and overall mortality has been reported in most observational studies examining this association.<sup>13,14</sup> Mortality is lowest at vitamin D levels in the 25 to 40 nmol/L range. At lower levels of serum vitamin D, mortality increases steeply, and overall mortality in the lowest quintile was more than 3 times that in the middle quintiles. Theodoratou et al (2014) identified 107 systematic reviews of observational studies examining the association between vitamin D levels and more than 100 different outcomes.<sup>15</sup>

### **Clinical Context**

The purpose of measuring vitamin D levels is to guide a treatment option that is an alternative to or an improvement on existing management in individuals who are asymptomatic without conditions or risk factors for which vitamin D supplementation is recommended.

The following PICO was used to select literature to inform this review.

**Populations**

The relevant population of interest is individuals who are asymptomatic without conditions or risk factors for which vitamin D supplement is recommended.

**Interventions**

The therapy being considered is testing of vitamin D levels.

**Comparators**

The following practice is currently being used to manage vitamin D deficiency: routine care without testing for vitamin D deficiency. Routine care may include recommendations for increased ultraviolet B exposure, dietary intake of vitamin D, or vitamin D supplementation in the absence of known vitamin D deficiency.

**Outcomes**

Relevant outcomes of interest are overall survival, test validity, symptoms, morbid events, and treatment-related morbidity.

The length of time needed to correct subclinical vitamin D deficiency and improve outcomes is unknown and likely varies for different clinical situations.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:


- To assess efficacy outcomes, comparative controlled prospective trials were sought, with preference for randomized controlled trials (RCTs);
- In the absence of such trials, comparative observational studies were sought, with preference for prospective studies.
- To assess longer term outcomes and adverse effects, single-arm studies that capture longer periods of follow up and/or larger populations were sought.

Studies with duplicative or overlapping populations were excluded.

**Analytic Framework**

Figure 1 summarizes the approach to this evidence review. The diagram demonstrates the framework for how vitamin D testing affects outcomes. Using this framework, the main question is whether testing individuals for vitamin D deficiency improves outcomes.

**Figure 1. Analytic Framework**



Based on this analytic framework, the most relevant studies for showing the clinical utility of vitamin D testing are trials that directly compare care including testing vitamin D levels against care without testing vitamin D levels. Should vitamin D screening in an asymptomatic, general population be shown to be effective, guidelines would then be needed to establish criteria for screening, screening intervals, and appropriate follow-up for positive tests. Indirect evidence of the utility of vitamin D testing would include evidence of the effectiveness of supplementation from trials testing supplementation to no supplementation in patients who are vitamin D deficient. Many of the existing RCTs, including the largest trial (Women’s Health Initiative), did not test vitamin D levels prior to treatment. Rather, they treated all patients enrolled regardless of vitamin D levels. Results of some of the main systematic reviews that take this approach will be reviewed, but this evidence is indirect and must be extrapolated from the treatment of all patients to the treatment of patients who are vitamin D deficient.

**Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

There is no consensus on how to define vitamin D deficiency or inadequacy, and there is no accepted reference standard. Available cutoffs for deficiency are neither standardized nor based on rigorous scientific studies.<sup>16</sup> Therefore, despite the availability of many tests that measure total serum 25-hydroxyvitamin D (25(OH)D) levels, their sensitivities and specificities for detecting clinically important deficiency are currently unknown.



**Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

No RCTs were found that evaluated clinical outcomes or harms in patients tested for vitamin D deficiency versus not tested for vitamin D deficiency. In the absence of direct evidence of the utility of testing, evidence of the effectiveness of vitamin D supplementation could indirectly support the utility of testing by identifying a group of patients in which baseline serum 25(OH)D is a predictor of supplement effect so that testing might be useful.

A large number of RCTs have evaluated the impact of vitamin D supplementation on outcomes. Theodoratou et al (2014) identified 87 meta-analyses of RCTs on vitamin D supplementation<sup>15</sup>; there were 21 meta-analyses on skeletal health, 7 on metabolic disease, 4 on pediatric outcomes, 3 on cardiovascular disease, 3 on pregnancy-related outcomes, and 18 on other outcomes. Because of the large literature base, this review of evidence will focus on the largest and most recent systematic reviews and meta-analyses of RCTs. Individual trials will be reviewed separately if they were not included in the meta-analyses or if particular features need highlighting. The evidence review includes use of vitamin D testing and supplementation in the following indications: skeletal health, cardiovascular disease, cancer, asthma, pregnancy, multiple sclerosis (MS), and overall mortality.

**REVIEW OF EVIDENCE****SKELETAL HEALTH****Systematic Reviews**

Numerous systematic reviews and meta-analyses of RCTs have been published evaluating the impact of vitamin D supplementation on skeletal health outcomes. The relevant health outcomes considered for this evidence review include fractures and falls. Studies that looked at bone mineral density and/or other physiologic measures of bone health were not included. Table 2 summarizes the results of systematic reviews performing quantitative meta-analyses on the relevant outcomes.

Among the trials included in the meta-analyses, few were large studies; most were small or moderate in size and limited by a small number of outcome events. Doses of vitamin D varied widely from 400 to 4800 IU/d; treatment and follow-up durations varied from 2 months to 7 years. Some studies limited enrollment to participants with low serum vitamin D. Most studies excluded institutionalized patients, but some included them. There was inconsistency in the results, especially for studies of fracture prevention, as evidenced by the relatively large degree of heterogeneity among studies.

**Table 2. Systematic Reviews Assessing the Impact of Vitamin D Supplementation on Skeletal Health**

Study	Outcome	No. of Studies	No. of Participants	$I^2$ , % <sup>a</sup>	RR for Outcome (95% CI)
<i>Patients with vitamin D deficiency</i>					
LeBlanc et al (2015) <sup>17</sup> ,	Any fracture	5	3551	32	0.98 (0.82 to 1.16)
	Hip fracture	4	1619	46	0.96 (0.72 to 1.29)
	Falls: total	5	1677	70	0.84 (0.69 to 1.02)
	Falls: person	5	1809	64.5	0.66 (0.50 to 0.88)
<i>All patients</i>					
Ling et al (2021) <sup>18</sup> ,	Falls	21	51,984	NR	1.00 (0.95 to 1.05)
Cranney et al (2011) <sup>6</sup> ; AHRQ	Any fracture	14	58,712	48.3	0.90 (0.81 to 1.01)
	Hip fracture	8	46,072	16.2	0.83 (0.68 to 1.0)
	Falls	9	9262	0	0.84 (0.76 to 0.93)
Avenell et al (2009) <sup>19</sup> ,	All fractures	10	25,016	NR	1.01 (0.93 to 1.09)
	Hip fractures	9	24,749	NR	1.15 (0.99 to 1.33)
	Vertebral fracture	5	9138	NR	0.90 (0.97 to 1.1)

Study	Outcome	No. of Studies	No. of Participants	I <sup>2</sup> , % <sup>a</sup>	RR for Outcome (95% CI)
Bischoff-Ferrari et al (2009) <sup>20</sup> ,	Non-vertebral fracture	5	7130	NR	0.79 (0.63 to 0.99)
Palmer et al (2009) <sup>21</sup> ,	All fractures (CKD-RD)	4	181	NR	1.0 (0.06 to 15.41)
Bischoff-Ferrari et al (2005) <sup>22</sup> ,	Hip fracture				
700 to 800 IU/d		3	5572	NR	0.74 (0.61 to 0.88)
400 IU/d		2	3722	NR	1.15 (0.88 to 1.50)
	Non-vertebral fracture				
700 to 800 IU/d		5	6098	NR	0.77 (0.68 to 0.87)
400 IU/d		2	3722	NR	1.03 (0.86 to 1.24)

AHRQ: Agency for Healthcare Research and Quality; CI: confidence interval; CKD-RD: chronic kidney disease on renal dialysis; NR: not reported; RR: relative risk.

<sup>a</sup> Heterogeneity value.

Cranney et al (2011) conducted a review for the Agency for Healthcare Research and Quality (AHRQ) on the effectiveness and safety of vitamin D in relation to bone health.<sup>6</sup> Reviewers concluded that:

- The evidence on the reduction in fractures was inconsistent. The combined results of trials using vitamin D<sub>3</sub> with calcium were consistent with a benefit on fractures, although the benefit was primarily found in the subgroup of elderly institutionalized women, which was a subgroup not included in this review.
- The evidence on a benefit in fall risk was also inconsistent. The results showed benefit in subgroups of postmenopausal women and in trials that used vitamin D in combination with calcium. There was a reduction in fall risk with vitamin D when 6 trials that adequately ascertained falls were combined.

A meta-analysis of double-blind RCTs by Bischoff-Ferrari et al (2005) estimated the benefit of vitamin D supplementation on fracture risk and examined the dose-response relation between vitamin D and outcomes.<sup>22</sup> Based on a meta-analysis of 5 RCTs that used high-dose vitamin D, reviewers concluded that supplementation at 700 to 800 IU/d reduced the incidence of hip fractures by 26%, and reduced any non-vertebral fracture by 23%. In this same review, based on the results of 2 RCTs, lower doses of vitamin D at 400 IU/d did not significantly reduce the fracture risk.

### **Randomized Controlled Trials**

The STURDY Collaborative Research Group (Appel et al 2021) was a large (N=688) RCT evaluating 4 doses of vitamin D in individuals at least 70 years of age at elevated fall risk and a serum vitamin D level of 25 to 72.5 nmol/L.<sup>23</sup> The primary outcome was time to first fall or death over 2 years. The primary outcome during the confirmatory stage was not significantly different between those receiving the control dose of vitamin D (200 IU/day) and those receiving what was considered the optimal dose of 1000 IU/day. Doses of 1000 IU/day or greater were associated with safety concerns. The study is limited by the use of vitamin D 200 IU/day as a control group rather than use of a placebo.

An RCT not included in most of the systematic reviews (Sanders et al [2010]<sup>24</sup>) reported results inconsistent with some of the previous trials and conclusions of meta-analyses. In this trial, 2256 community-dwelling elderly individuals at high-risk for falls were treated with high-dose vitamin D 500,000 IU orally once per year for 3 to 5 years. There was a 15% increase in falls for the group treated with vitamin D ( $p=.03$ ) and a 26% increase in fractures ( $p=.02$ ). In addition, there was a temporal relation to the increase in fall risk, with the greatest risk in the period immediately after vitamin D administration. It is unclear whether the specific regimen used in this study (e.g., high-dose vitamin D once/year) was responsible for the different results seen in this study compared with prior research.

### **Section Summary: Skeletal Health**

Numerous RCTs and meta-analyses of RCTs have been published on the effect of vitamin D supplementation on skeletal health. The most direct evidence consists of trials that selected patients for vitamin D deficiency and randomized patients to vitamin D or placebo. A meta-analysis of these trials showed no reduction in fractures and an uncertain reduction in falls. In meta-analyses that treated all patients regardless of vitamin D levels, there are inconsistent findings on the effect of supplementation on fractures and falls. There is some evidence that subgroups (e.g., elderly women) may benefit from supplementation and that higher doses may provide a benefit whereas lower doses do not; however, very high doses may increase the risk of falls. Therefore, the evidence does not convincingly demonstrate an improvement in skeletal health outcomes with vitamin D supplementation.

## **CARDIOVASCULAR DISEASE**

### **Systematic Reviews**

A large number of trials have reported on the impact of vitamin D supplementation on cardiovascular events. A number of systematic reviews have examined the relation between vitamin D and cardiovascular outcomes.

Elamin et al (2011) published a systematic review and meta-analysis evaluating cardiovascular outcomes.<sup>25</sup> It included 51 trials that used various forms of vitamin D with or without calcium. There was minimal heterogeneity among the studies. Combined analysis showed no significant impact on cardiovascular death (relative risk [RR]=0.96; 95% confidence interval [CI], 0.93 to 1.0), myocardial infarction (RR=1.02; 95% CI, 0.93 to 1.13), or stroke (RR=1.05; 95% CI, 0.88 to 1.25). No significant effects were found on the physiologic outcomes of lipids, glucose, or blood pressure.

A systematic review by Pittas et al (2010) assessed 5 RCTs evaluating the impact of vitamin D supplementation on incident cardiovascular disease.<sup>26</sup> None of the 5 trials reported a significant reduction in cardiovascular outcomes in the vitamin D group. Combined analysis of these trials found a RR for cardiovascular outcomes of 1.08 (95% CI, 0.99 to 1.19) in the vitamin D group.

An AHRQ report by Chung et al (2009) concluded that<sup>27</sup>:

- The evidence on the impact of vitamin D on cardiovascular outcomes is inconsistent, and conclusions are difficult to make because of the marked heterogeneity of the evidence.
- The RCTs that have evaluated the impact of vitamin D on cardiovascular outcomes use cardiovascular events as a secondary outcome, not as a prespecified primary outcome.
- These analyses have been hampered by low numbers of cardiovascular events and imperfect methods for the ascertainment of cardiovascular events.

Wang et al (2008) also performed a systematic review of whether vitamin D and calcium prevent cardiovascular events.<sup>28</sup> Eight RCTs of vitamin D supplementation in the general population evaluated cardiovascular outcomes as a secondary outcome. A combined analysis of studies that used high-dose vitamin D supplementation ( $\gg 1000$  IU/d) found a 10% reduction in cardiovascular events, but this reduction was not statistically significant (RR=0.90; 95% CI, 0.77 to 1.05). When studies that combined vitamin D plus calcium supplementation were included, there was no trend toward a benefit (RR=1.04; 95% CI, 0.92 to 1.18).

A systematic review by Pittas et al (2010) included 10 intervention trials that evaluated the relation between vitamin D and hypertension.<sup>26</sup> Most did not report a decrease in incident hypertension associated with vitamin D supplementation.

A systematic review by Su et al (2021) assessed 36 studies that included cohort studies, RCTs, and case-control analyses for the association between serum levels of vitamin D and risk of stroke.<sup>29</sup> Lower levels of serum vitamin D were associated with an elevated risk of stroke in both Asian and White populations, however, vitamin D supplementation did not show benefit in decreasing the risk of stroke. In a meta-analysis limited to RCTs, Fu et al (2022) had similar findings; vitamin D did not reduce stroke risk compared with placebo (RR=1.02; 95% CI, 0.93 to 1.13;  $p=.65$ ).<sup>30</sup>

### **Section Summary: Cardiovascular Disease**

The available evidence does not support a benefit of vitamin D supplementation on cardiovascular events. Numerous RCTs have assessed this outcome; however, in most studies, it is a secondary outcome with a limited number of events, thus limiting the power to detect a difference. Furthermore, it is difficult to separate the impact of vitamin D from the impact of calcium in many of these studies. It is common to use vitamin D and calcium supplementation together. Research has also highlighted a potential increase in cardiovascular outcomes associated with calcium supplementation.<sup>31</sup> Thus, if there are beneficial effects of vitamin D, they may be obscured or attenuated by the concomitant administration of calcium supplements. Another possibility is that vitamin D and calcium act synergistically, promoting either a greater protective effect against cardiovascular disease or an increase in cardiovascular risk.

## **CANCER**

### Systematic Reviews

Systematic reviews have evaluated the effect of vitamin D supplementation on the prevention of cancer. Table 3 contains characteristics of 2 systematic reviews, and Table 4 summarizes the results of the meta-analyses performed in the reviews. The individual RCTs included in the systematic reviews are listed in Table 5. Both systematic reviews by Keum et al (2019) and Bjelakovic et al (2014) found that vitamin D supplementation did not reduce cancer incidence compared to placebo or no intervention; however, total cancer mortality was reduced.<sup>32,33</sup> In the systematic review by Bjelakovic et al, there was no substantial difference in the effect of vitamin D on cancer in subgroup analyses of trials only including participants with vitamin D levels less than 20 ng/mL at enrollment compared with trials including participants with vitamin D levels of 20 ng/mL or greater at enrollment. Notably, most included studies were not designed to assess cancer incidence or mortality. The authors of the systematic review by Bjelakovic et al (2014) noted that the estimates that were significantly different were at high risk of type I error due to sample size and potential attrition bias.

**Table 3. Characteristics of Systematic Reviews Assessing Vitamin D and Cancer**

Study; Trial	Dates	Trials	Participants	N	Design	Duration
Keum et al (2019) <sup>32</sup> ,	To November 2018	10	People with baseline 25(OH)D	NR	RCTs	3 to 10 years
Bjelakovic et al (2014) <sup>33</sup> ,	To February 2014	18	Adults (over 18 years) (healthy, with stable disease, or diagnosed with vitamin D deficiency)	50,623	RCTs	5 months to 7 years

25(OH)D: 25-hydroxyvitamin D; NR: not reported; RCT: randomized controlled trial.

**Table 4. Results of Systematic Reviews Assessing Vitamin D and Cancer**

Study	Total Cancer Incidence	Total Cancer Mortality	Total Mortality	Nephrolithiasis
Keum et al (2019) <sup>32</sup> ,				
<b>Total N</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>
Pooled effect	RR=0.98	RR=0.87	RR=0.93	NR
95% CI	0.93 to 1.03	0.79 to 0.96	0.88 to 0.98	NR
$I^2$	0	0	0	NR
Bjelakovic et al (2014) <sup>33</sup> ,				
<b>Total N</b>	<b>50,623</b>	<b>44,492 (Vitamin D<sub>3</sub> only)</b>	<b>49,866</b>	<b>42,573</b>
Pooled effect	RR=1.00	RR=0.88	RR=0.93	RR=1.17
95% CI	0.94 to 1.06	0.78 to 0.98	0.88 to 0.98	1.03 to 1.34

Study	Total Cancer Incidence	Total Cancer Mortality	Total Mortality	Nephrolithiasis
<i>I</i> <sup>2</sup>	0	0	0	0

CI: confidence interval; NR: not reported; RR: relative risk.

**Table 5. Comparison of Randomized Controlled Trials Included in the Systematic Reviews**

Primary Study (Year)	Keum et al (2019) <sup>32,</sup>	Bjelakovic et al (2014) <sup>33,</sup>
Ott et al (1989) <sup>34,</sup>		●
Grady et al (1991) <sup>35,</sup>		●
Komulainen et al (1999) <sup>36,</sup>		●
Gallagher et al (2001) <sup>37,</sup>		●
Trivedi et al (2003) <sup>38,</sup>	●	●
Wactawski-Wende et al (2006) <sup>39,</sup>	●	
Daly et al (2008) <sup>40,</sup>		●
LaCroix et al (2009) <sup>41,</sup>	●	
Bolton-Smith et al (2007) <sup>42,</sup>		●
Lappe et al (2007) <sup>43,</sup>	●	●
Prince et al (2008) <sup>44,</sup>		●
Janssen et al (2010) <sup>45,</sup>		●
Sanders et al (2010) <sup>24,</sup>	●	●
Brunner et al (2011) <sup>46,</sup>		●
Avenell et al (2012) <sup>47,</sup>	●	●
Glendenning et al (2012) <sup>48,</sup>		●
Larsen et al (2012) <sup>49,</sup>		●
Murdoch et al (2012) <sup>50,</sup>		●
Wood et al (2012) <sup>51,</sup>		●
Witham et al (2013) <sup>52,</sup>		●
Baron et al (2015) <sup>53,</sup>	●	
Jorde et al (2016) <sup>54,</sup>	●	
Lappe et al (2017) <sup>55,</sup>	●	
Scragg et al (2018) <sup>56,</sup>	●	

Primary Study (Year)	Keum et al (2019) <sup>32</sup> ,	Bjelakovic et al (2014) <sup>33</sup> ,
Manson et al (2019) <sup>57</sup> ,	●	

### Section Summary: Cancer

Systematic reviews of many RCTs have examined the effect of vitamin D supplementation on cancer outcomes, although cancer was not the prespecified primary outcome in most RCTs. The current evidence does not demonstrate that vitamin D supplementation reduces the incidence of cancer.

## ASTHMA

### Systematic Reviews

Several systematic reviews of vitamin D supplementation for the prevention of asthma exacerbations have been published. Four recent reviews are summarized in Tables 6 and 7. Twenty-six unique RCTs were included in these systematic reviews (see Table 8). Reviews by Williamson et al (2023), Liu et al (2022),<sup>58</sup> and Jolliffe et al (2017)<sup>59</sup>, concluded that the RCTs were generally at low risk of bias. The RCTs included children and adults, as well as variable doses of vitamin D, routes and lengths of administration, and variable levels of asthma severity. The RCTs also included patients with variable baseline 25(OH)D levels and patients were not generally selected by baseline 25(OH)D.

The most recent Cochrane systematic review evaluating vitamin D for asthma management by Williamson et al (2023)<sup>60</sup>, failed to find improved outcomes with vitamin D use, reversing conclusions of a 2016 Cochrane review by Martineau et al (2016).<sup>61</sup> The Jolliffe et al (2017) review found that vitamin D supplementation reduced the rate (or proportion) of asthma exacerbations requiring treatment with systemic corticosteroids, while Liu et al (2022) found vitamin D supplementation to reduce overall asthma exacerbations. The review by Luo et al (2015)<sup>62</sup>, found that vitamin D had no effect on Asthma Control Test (ACT) scores, forced expiratory volume in 1-second (FEV1) outcomes, or rates of adverse events. Liu et al (2022) found no benefit to vitamin D supplementation on ACT scores, FEV1, or Fractional Exhaled Nitric Oxide (FENO).<sup>58</sup> The review by Jolliffe et al (2017) used individual participant data and was, therefore, able to test for patient-level subgroup effects. For the outcome of "rate of asthma exacerbations treated with systemic corticosteroids," the protective effect of vitamin D was larger in patients with a baseline 25(OH)D levels of less than 25 nmol/L (rate ratio=0.33; 95% CI, 0.11 to 0.98) compared with patients who had higher a baseline 25(OH)D levels (rate ratio=0.77; 95% CI, 0.58 to 1.03). However, the subgroup by treatment group interaction was not statistically significant (p=.25).



**Table 6. Characteristics of Systematic Reviews Assessing Vitamin D and Asthma**

Study; Trial	Dates	Trials	Participants	N	Design	Duration
Williamson et al (2023) <sup>60</sup> ,	To Sep 2022	20	People with asthma, all ages, and baseline 25(OH)D levels included	2474	RCT	3 mo to 40 mo
Liu et al (2022) <sup>58</sup> ,	The decade prior to publication	10	Asthma patients who received any form or dose of vitamin D	1349	RCT	9 wks to 12 mo
Jolliffe et al (2017) <sup>59</sup> ; PROSPERO CRD42014013953	To Oct 2016	8	People with asthma, all ages, and baseline 25(OH)D levels included	1078	Randomized, double-blind, placebo-controlled	15 wk to 12 mo
Luo et al (2015) <sup>62</sup> ,	1946 to 2015	7	People with asthma, all ages, and baseline 25(OH)D levels included	903	RCT	9 wk to 12 mo

RCT: randomized controlled trial; 25(OH)D: 25-hydroxyvitamin D.

**Table 7. Results of Systematic Reviews Assessing Vitamin D and Asthma**

Study	Asthma Exacerbation	Asthma Exacerbation Requiring SCS	ACT Score	FEV <sub>1</sub>	Proportion of Patients With AEs
Williamson et al (2023) <sup>60</sup> ,					
<b>Total N</b>	1070	1778	1271	1286	1556
Pooled effect	OR=0.56	OR=1.04 <sup>a</sup>	SMD=0.23 higher	Diff=0.2% higher <sup>b</sup>	OR=0.89 <sup>d</sup>
95% CI	0.81 to 1.34	0.26 to 1.21	0.26 lower to 0.73 higher	1.24 lower to 1.63 higher	0.56 to 1.41
<i>I</i> <sup>2</sup>	33%	60%	29%	25%	0%
Liu et al (2022) <sup>58</sup> ,					
<b>Total N</b>	<b>944</b>		<b>526</b>	<b>651</b>	
Pooled effect	Risk ratio=0.60		SMD=0.04	SMD=0.04	
95% CI	0.41 to 0.88		-0.13 to 0.21	-0.35 to 0.43	
<i>I</i> <sup>2</sup>	64%		0%	78%	
Jolliffe et al (2017) <sup>59</sup> ,					
<b>Total N</b>	<b>868</b>	<b>955</b>	<b>NR</b>	<b>NR</b>	<b>955</b>

Study	Asthma Exacerbation	Asthma Exacerbation Requiring SCS	ACT Score	FEV <sub>1</sub>	Proportion of Patients With AEs
Pooled effect	HR=0.78	RR=0.74			OR=0.87 <sup>d</sup>
95% CI	0.55 to 1.10	0.56 to 0.97			0.46 to 1.63
<i>I</i> <sup>2</sup>	NA	NA			
Luo et al (2015) <sup>62</sup> ,					
<b>Total N</b>	<b>820</b>	<b>NR</b>	<b>250</b>	<b>316</b>	<b>326</b>
Pooled effect	OR=0.66		Diff = -0.05	Diff = -0.02 <sup>c</sup>	OR=1.16
95% CI	0.32 to 1.37		-0.30 to 0.20	-0.15 to 0.11	0.74 to 1.81
<i>I</i> <sup>2</sup>	81%		NA	0%	0%

ACT: Asthma Control Test; AE: adverse event; Diff: difference; CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume in 1 second; HR: hazard ratio; NA: not applicable; NR: not reported; OR: odds ratio; RR: rate ratio ; SCS: systemic corticosteroid; SMD: standard mean difference.

<sup>a</sup> Outcome was proportion with ≥1 exacerbation.

<sup>b</sup> FEV<sub>1</sub>, % predicted.

<sup>c</sup> At 12 months.

<sup>d</sup> Serious adverse events.

**Table 8. Comparison of Randomized Controlled Trials Included in the Systematic Reviews**

Primary Study (Year)	Williamson et al (2023) <sup>60</sup> ,	Liu et al (2022) <sup>58</sup> ,	Jolliffe et al (2017) <sup>59</sup> ,	Luo et al (2015) <sup>62</sup> ,
Ramos-Martinez et al (2018) <sup>63</sup> ,	●			
Jiang et al (2017) <sup>64</sup> ,	●			
Jerzynska et al (2016) <sup>65</sup> ,	●			
Forno et al (2020) <sup>66</sup> ,	●			
Ducharme et al (2019) <sup>67</sup> ,	●			
Camargo et al (2021) <sup>68</sup> ,	●			
Andújar-Espinosa et al (2021) <sup>69</sup> ,	●			
Aglipay et al (2019) <sup>70</sup> ,	●			
Worth et al (1994) <sup>71</sup> ,				●
Majak et al (2009) <sup>72</sup> ,	●			●
Urashima et al (2010) <sup>73</sup> ,	●		●	
Majak et al (2011) <sup>74</sup> ,	●	●	●	

Primary Study (Year)	Williamson et al (2023) <sup>60,</sup>	Liu et al (2022) <sup>58,</sup>	Jolliffe et al (2017) <sup>59,</sup>	Luo et al (2015) <sup>62,</sup>
Lewis et al (2012) <sup>75,</sup>	●			
Baris et al (2014) <sup>76,</sup>				●
Castro et al (2014) <sup>77,</sup>	●	●	●	●
Yadav et al (2014) <sup>78,</sup>	●	●		●
de Groot et al (2015) <sup>79,</sup>		●		●
Martineau et al (2015) <sup>80,</sup>	●	●	●	●
Tachimoto et al (2016) <sup>81,</sup>	●		●	
Jensen et al (2016) <sup>82,</sup>	●		●	
Kerley et al (2016) <sup>83,</sup>	●		●	
Musharraf et al (2017) <sup>84,</sup>		●		
Dodamani et al (2019) <sup>85,</sup>		●		
Shabana et al (2019) <sup>86,</sup>		●		
Jat et al (2021) <sup>87,</sup>	●	●		
Thakur et al (2021) <sup>88,</sup>	●	●		

### Randomized Controlled Trials

An RCT of prenatal supplementation in 881 pregnant women at high-risk of having children with asthma was published in 2016.<sup>89</sup> Women between gestational ages of 10 and 18 weeks were randomized to daily vitamin D 4000 IU plus a multivitamin containing vitamin D 400 IU (4400 IU group) or daily placebo vitamin D plus a multivitamin containing vitamin D 400 IU (400 IU group). Coprimary outcomes were (1) parental report of physician-diagnosed asthma or recurrent wheezing through 3 years of age and (2) third trimester maternal 25-OH(D) levels. Analysis of infant outcomes included 806 infants, 218 of whom developed asthma by age 3 years. The proportion of infants with asthma or recurrent wheeze was 24% in the 4400 IU group vs 30% in the 400 IU group (difference= -6%; 95% CI, -30% to 18%). There were no differences in the proportion of infants experiencing eczema or lower respiratory tract infections.

### Section Summary: Asthma

Results of systematic reviews have reported mixed findings with respect to the effect of vitamin D supplementation on asthma outcomes. Populations included in studies varied by baseline vitamin D deficiency levels, administration of vitamin D, and the severity of asthma. In general, patients were not selected based on a low baseline 25(OH)D level. While there is some evidence that vitamin D supplementation reduces the rate of asthma exacerbations, it is unclear if baseline 25(OH)D level is related to treatment benefit. The current evidence is insufficient to determine the effect of vitamin D supplementation on asthma outcomes.

## PREGNANCY

### Systematic Reviews

A systematic review of studies examining the role of vitamin D supplementation in pregnancy is summarized in Table 9 and Table 10. The individual studies included in the systematic review are listed in Table 11. Vitamin D supplementation during pregnancy probably reduces risk of pre-eclampsia (moderate-certainty evidence), gestational diabetes (moderate-certainty evidence), severe postpartum hemorrhage (low-certainty evidence), and low birthweight in infants (moderate-certainty evidence).<sup>90</sup> However, not all studies measured baseline 25(OH)D levels and analyses based on initial 25(OH)D concentrations were not performed. Most studies were considered to have a low-moderate risk of bias.

**Table 9. Characteristics of Systematic Review Assessing Vitamin D and Pregnancy**

Study; Trial	Dates	Trials	Participants	N	Design	Duration
Palacios et al (2019) <sup>90</sup> ,	To July 2018	22 <sup>a</sup> (vitamin D supplementation alone)	Pregnant women; most studies included baseline 25(OH)D levels	3725	RCTs	NR (most studies started supplementation at or after 20 weeks gestation)

25(OH)D: 25-hydroxyvitamin D; NR: not reported; RCT: randomized controlled trial.

<sup>a</sup> Results of meta-analysis evaluating vitamin D supplementation + calcium not reported.

**Table 10. Results of Systematic Review Assessing Vitamin D and Pregnancy**

Study	Pre-eclampsia	Gestational diabetes	Maternal AE: Severe postpartum hemorrhage	Preterm birth (<37 weeks' gestation)	Low birthweight (<2500 gram)
Palacios et al (2019) <sup>90</sup> ,					
<b>Total N</b>	<b>499</b>	<b>446</b>	<b>1134</b>	<b>1640</b>	<b>697</b>
Pooled effect	RR=0.48	RR=0.51	RR=0.68	RR=0.66	RR=0.55
95% CI	0.30 to 0.79	0.27 to 0.97	0.51 to 0.91	0.34 to 1.3	0.35 to 0.87

AE: adverse event; CI: confidence interval; RR: relative risk.

**Table 11. Randomized Controlled Trials Included in the Systematic Review**

Primary Study (Year)	Palacios et al (2019) <sup>90</sup> ,
Brooke et al (1980) <sup>91</sup> ,	●
Delvin et al (1986) <sup>92</sup> ,	●
Mallet et al (1986) <sup>93</sup> ,	●
Marya et al (1988) <sup>94</sup> ,	●
Kaur et al (1991) <sup>95</sup> ,	●

Primary Study (Year)	Palacios et al (2019) <sup>90,</sup>
Yu et al (2008) <sup>96,</sup>	●
Roth et al (2010) <sup>97,</sup>	●
Sabet et al (2012) <sup>98,</sup>	●
Asemi et al (2013) <sup>99,</sup>	●
Grant et al (2013) <sup>100,</sup>	●
Tehrani et al (2014) <sup>101,</sup>	●
Mirghafourvand et al (2015) <sup>102,</sup>	●
Rodda et al (2015) <sup>103,</sup>	●
Sablok et al (2015) <sup>104,</sup>	●
Singh et al (2015) <sup>105,</sup>	●
Khan et al (2016) <sup>106,</sup>	●
Cooper et al (2016) <sup>107,</sup>	●
Naghshineh et al (2016) <sup>108,</sup>	●
Shahgheibi et al (2016) <sup>109,</sup>	●
Vaziri et al (2016) <sup>110,</sup>	●
Sasan et al (2017) <sup>111,</sup>	●
Samimi et al (2017) <sup>112,</sup>	●

### Section Summary: Pregnancy

A systematic review found vitamin D supplementation in pregnancy reduced the risk of pre-eclampsia, gestational diabetes, low birthweight, and possibly severe postpartum hemorrhage; however, the significance of baseline 25(OH)D levels was not defined.

### Multiple Sclerosis

Three systematic reviews have examined the effect of vitamin D supplementation in patients with MS.<sup>113,114,115</sup> Reviewers described 6 RCTs, all of which were small (N<100). Patient follow-up ranged from 6 months to 2 years, and the dosing and administration of vitamin D varied. None of the trials reported improvement in MS relapse rates; most trials showed no effect of vitamin D on any of the surrogate or clinical outcomes. Only 1 trial reported improvement in magnetic resonance imaging of lesions in the vitamin D supplementation group. The evidence for vitamin D supplementation in MS is poor.

## OVERALL MORTALITY

### Systematic Reviews

A number of meta-analyses of RCTs of vitamin D supplementation have examined the benefit of vitamin D supplementation on overall mortality. Table 12 summarizes the most recent meta-

analyses. The individual studies ranged in size from fewer than 100 to several thousand patients. No significant heterogeneity was reported for these trials.

The most relevant information comes from a meta-analysis of patients with vitamin D deficiency by LeBlanc et al (2015).<sup>116</sup> This report included 11 studies and found a marginally significant reduction in overall mortality, with a CI that approached 1.0. When the subgroup analysis was performed, it became apparent that most of the benefit was specific to institutionalized patients whereas, in community-dwelling patients, the data revealed no reduction in mortality.

The AHRQ report by Newberry et al (2014),<sup>117</sup> assessing the health effects of vitamin D supplementation, updated the original 2007 report. A quantitative synthesis of all trials was not performed in the 2014 update. Rather reviewers identified areas where the new trials might change previous conclusions. Their main conclusions were that the results did not support a benefit on overall mortality associated with vitamin D supplementation. No important trials identified in the update would potentially change this conclusion.

For meta-analyses including RCTs that treated all patients with vitamin D, most analyses have not shown a significant reduction in mortality. The single analysis that did show a significant reduction was that by Chowdhury et al (2014), who reported a marginally significant result for vitamin D<sub>3</sub> supplementation but not for vitamin D<sub>2</sub> supplementation.<sup>118</sup>

**Table 12. Results of Systematic Reviews of Randomized Controlled Trials Assessing the Impact of Vitamin D Supplementation on Mortality**

Study	Outcome	No. of Studies	No. of Participants	I <sup>2</sup> , % <sup>a</sup>	RR for Outcome (95% CI)
Patients with vitamin D deficiency					
Leblanc et al (2015) <sup>116</sup> ,	Mortality (all patients)	11	4126	0	0.83 (0.70 to 0.99)
	Mortality (noninstitutionalized patients)	8	2947	0	0.93 (0.73 to 1.18)
All patients					
Bjelakovic et al (2014) <sup>119</sup> ,	Mortality (vitamin D <sub>3</sub> )	13	12,609	5%	0.92 (0.85 to 1.00)
	Mortality (vitamin D <sub>2</sub> )	8	17,079	14%	1.03 (0.96 to 1.12)
Chowdhury et al (2014) <sup>118</sup> ,	Mortality (vitamin D <sub>3</sub> )	14	13,367	0	0.89 (0.80 to 0.99)
	Mortality (vitamin D <sub>2</sub> )	8	17,079	0	1.04 (0.97 to 1.11)
Palmer et al (2009) <sup>21</sup> ,	Mortality (CKD-RD)	5	233		1.34 (0.34 to 5.24)

Study	Outcome	No. of Studies	No. of Participants	I <sup>2</sup> , % <sup>a</sup>	RR for Outcome (95% CI)
Palmer et al (2009) <sup>120</sup> ,	Mortality (CKD)	4	477		1.40 (0.38 to 5.15)

CI: confidence interval; CKD: chronic kidney disease; CKD-RD: chronic kidney disease on renal dialysis; RCT: randomized controlled trial; RR: relative risk.

<sup>a</sup> Heterogeneity value.

### Section Summary: Overall Mortality

Evidence from a number of systematic reviews and meta-analyses does not support a benefit of vitamin D supplementation on overall mortality for the general, noninstitutionalized population. Populations included in the studies varied by baseline vitamin D deficiency and administration of vitamin D.

### SUPPLEMENTAL INFORMATION

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

### Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

### American College of Obstetrics and Gynecology

The American College of Obstetrics and Gynecology (2011, reaffirmed 2021) issued a committee opinion on the testing of vitamin D levels and vitamin D supplementation in pregnant women.<sup>121</sup> The following recommendation was made concerning testing vitamin D levels:

"At this time there is insufficient evidence to support a recommendation for screening all pregnant women for vitamin D deficiency. For pregnant women thought to be at increased risk of vitamin D deficiency, maternal serum 25-hydroxyvitamin D levels can be considered and should be interpreted in the context of the individual clinical circumstance. When vitamin D deficiency is identified during pregnancy, most experts agree that 1,000-2,000 international units per day of vitamin D is safe."

### Bone Health and Osteoporosis Foundation

The Bone Health and Osteoporosis Foundation updated recommendations for the prevention and treatment of osteoporosis in 2021.<sup>3</sup> They recommended monitoring serum 25-hydroxy vitamin D levels in postmenopausal women and men 50 years of age and older, and vitamin D supplementation as necessary to maintain levels between 30 and 50 ng/mL.

### Endocrine Society

In 2011, the Endocrine Society published clinical practice guidelines on the evaluation, treatment, and prevention of vitamin D deficiency.<sup>122</sup> The following recommendations were made regarding testing vitamin D levels:

- 25-hydroxy vitamin D serum level testing is recommended: “to evaluate vitamin D status only in patients who are at risk of deficiency.” The guideline did not recommend screening of individuals not at risk of vitamin D deficiency.
- 1,25-dihydroxyvitamin D testing was not recommended to evaluate vitamin D status. However, the guideline did recommend monitoring calcitriol levels under certain conditions.

### U.S. Preventive Services Task Force Recommendations

The U.S. Preventive Services Task Force published an updated recommendation<sup>123</sup>, and associated evidence report and systematic review in 2021<sup>124</sup>, on vitamin D screening. The Task Force concluded that the current evidence was insufficient to assess the balance of benefits and harms of screening for vitamin D deficiency in asymptomatic individuals (grade I [insufficient evidence]).

### Ongoing and Unpublished Clinical Trials

Some currently ongoing or unpublished trials that might influence this review are listed in Table 13.

**Table 13. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
<b>Ongoing</b>			
NCT05431920	Effects of Vitamin D3 Supplementation in Asthma Control, Pulmonary Function and Th17 Inflammatory Biomarkers in Adolescents With Asthma, Obesity and Vitamin D Deficiency: a Randomized Clinical Trial	264	Aug 2024
NCT05043116	High-dose Vitamin D Supplement for the Prevention of Acute Asthma-like Symptoms in Preschool Children - a Double-blind, Randomized, Controlled Trial	320	Oct 2031
NCT05329428	PREDIN: Pregnancy and Vitamin D Intervention Study - A Randomized Controlled Trial	102	Dec 2024
NCT05208827	A Multicenter Randomized Controlled Study of Vitamin D Supplementation in Pregnant Women for the Prevention of Gestational Diabetes.	1600	Jan 2025
NCT04291313	Vitamin D Deficiency in Pregnancy - Identifying Associations and Mechanisms Linking Maternal Vitamin D Deficiency to Placental Dysfunction and Adverse Pregnancy Outcomes	2000	May 2023
NCT00856947	Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood: An Interventional Trial in the ABC (Asthma Begins in Childhood) Cohort	600	Jul 2027
<b>Unpublished</b>			
NCT04117581	A Daily 5000 IU Vitamin D Supplement for the Improvement of Lung Function and Asthma Control in Adults With Asthma: a Randomised Controlled Trial	32 (actual)	Apr 2022

NCT: national clinical trial.



**CODING**

**The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.**

**Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

**The code(s) listed below are medically necessary ONLY if the procedure is performed according to the "Policy" section of this document.**

<b>CPT/HCPCS</b>	
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed
82652	Dihydroxyvitamin D, 1, 25 dihydroxy, includes fraction(s), if performed
0038U	Vitamin D, 25 hydroxy D2 and D3, by LCMS/MS, serum microsample, quantitative

<b>REVISIONS</b>	
03-08-2010	Updated Description section
	In Coding Section: <ul style="list-style-type: none"> <li>▪ Removed CPT code: 82307 (effective 01/01/2010)</li> <li>▪ Updated wording for CPT codes: 82306, 82652 (effective 01/01/2010)</li> </ul>
	Updated References
10-26-2010	Updated Description section
	In Policy section: <ul style="list-style-type: none"> <li>▪ To emphasize the need for recommended vitamin D supplementation prior to testing, revised the wording from: "A. Conditions for which testing for vitamin D deficiency may be considered medically necessary, include:" to: "A. Testing for vitamin D deficiency is considered not medically necessary except when: 1. The recommended vitamin D supplementation is being taken AND 2. One of the following conditions is present:"</li> </ul>
	In Coding section: <ul style="list-style-type: none"> <li>▪ Updated diagnosis coding from 345.0-345.9 to 345.00-345.91</li> </ul>
01-28-2011	Updated Description section.
	Updated Reference section.
	In Coding section: <ul style="list-style-type: none"> <li>▪ Addition of diagnosis codes: 252.1 and 775.4.</li> </ul>
03-28-2011	In Coding section: <ul style="list-style-type: none"> <li>▪ Addition of Diagnosis codes: 242.00-242.31, 242.90, 242.91.</li> <li>▪ Removed Diagnosis code 268.9.</li> </ul>
	Updated Reference section
09-29-2011	Updated the Description section.
	In the Policy Language section: <ul style="list-style-type: none"> <li>▪ In Item A, #2, h, added "oral anti-fungals,"</li> </ul>

<b>REVISIONS</b>	
	<ul style="list-style-type: none"> <li>▪ In Item A, #2, added the following:               <ul style="list-style-type: none"> <li>○ "o. muscle weakness</li> <li>○ p. history of falls</li> <li>○ q. history of vitamin D deficiency"</li> </ul> </li> </ul>
	<p>In the Coding section:</p> <ul style="list-style-type: none"> <li>▪ Added the following diagnosis codes: 135, 263-263.8, 268.9, 275.41, 275.49, 555.0-555.9, 556.0, 556.1, 556.2, 556.3, 556.6, 556.8, 556.9, 577.1, 579.0-579.9, 728.87</li> </ul>
	Updated the Reference section.
12-20-2011	<p>In the Coding Section:</p> <ul style="list-style-type: none"> <li>▪ Added the following diagnosis codes: 277.00, 277.02, 277.03, 277.9</li> </ul>
02-05-2014	<p>Policy reviewed.</p> <p>In Policy section:</p> <ul style="list-style-type: none"> <li>▪ In Item A, 2, inserted "r. Post-transplant"</li> </ul> <p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Added ICD-10 Diagnosis (<i>Effective October 1, 2014</i>)</li> </ul>
10-01-2015	<p>Policy published 11-25-2015. Effective 10-01-2015 with ICD-10 coding implementation.</p> <p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Added ICD-10 codes: E55.9, Z79.52.</li> </ul>
10-01-2015	<p>Policy published 01-13-2016. Effective 10-01-2015 with ICD-10 coding implementation.</p> <p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Added ICD-10 code: M85.89.</li> </ul>
10-01-2015	<p>Policy published 03-25-2016. Effective 10-01-2015 with ICD-10 coding implementation.</p> <p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Added ICD-10 code Z91.81</li> </ul> <p>Updated References section.</p>
06-10-2016	<p>Updated Description section.</p> <p>In Policy section:</p> <ul style="list-style-type: none"> <li>▪ In Item A, removed "is", "not", and "except", and added "may be", "in patients with signs and/or symptoms of vitamin D deficiency or toxicity (see Policy Guidelines)", and "one of the high-risk factors is present" to read "Testing for Vitamin D deficiency may be considered medically necessary in patients with signs and/or symptoms of vitamin D deficiency or toxicity (see Policy Guidelines) when one of the high-risk factors is present:"</li> <li>▪ Removed previous Item A 1, "The recommended vitamin D supplementation is being taken AND"</li> <li>▪ Removed previous Item A 2, "One of the following conditions is present"</li> <li>▪ Removed previous Item A 2 c, "hyperthyroidism"</li> <li>▪ Removed previous Item A 2 e, "heritable disorders of Vitamin D metabolism"</li> <li>▪ Removed previous Item A 2 i, "obesity"</li> <li>▪ Removed previous Item A 2 m, "phosphaturia"</li> <li>▪ Removed previous Item A 2 o, "muscle weakness"</li> <li>▪ Removed previous Item A 2 p, "history of falls"</li> <li>▪ In current Item A 1, added ", stage <math>\geq 3</math>" to read "chronic kidney disease, stage <math>\geq 3</math>"</li> <li>▪ In current Item A 2, removed "disorder" and added "diseases" to read "granulomatous diseases"</li> <li>▪ In current Item A 3, removed "hyperparathyroidism" and added "parathyroid disorders"</li> <li>▪ In current Item A 4, removed "liver failure" and added "cirrhosis/chronic liver disease"</li> <li>▪ In current Item A 5, added "states" to read "malabsorption states"</li> </ul>

<b>REVISIONS</b>	
	<ul style="list-style-type: none"> <li>▪ In current Item A 6, removed "(oral antifungals, AIDS medications)" and added "chronic use of" to read "chronic use of anticonvulsant medications or corticosteroids"</li> <li>▪ In current Item A 11, removed "history of vitamin D deficiency" and added "vitamin D deficiency, in replacement"</li> <li>▪ Added Item A 12, "hypo- or hypercalcemia"</li> <li>▪ Added Item A 13, "obstructive jaundice/biliary tract disease"</li> <li>▪ Added Item A 14, "osteogenesis imperfecta"</li> <li>▪ Added Item A 15, "osteosclerosis/osteopetrosis"</li> <li>▪ Added Item B, Item B 1, and Item B 2, "Testing vitamin D levels in asymptomatic patients may be considered medically necessary in the following patient populations:                             <ol style="list-style-type: none"> <li>1. Individuals who have risk factors for vitamin D deficiency (as listed in Item A above)</li> <li>2. Institutionalized patients (see Policy Guidelines)"</li> </ol> </li> <li>▪ Added Item C, "Testing vitamin D levels in asymptomatic patients is considered not medically necessary when the above criteria are not met."</li> <li>▪ Added Policy Guidelines</li> </ul>
	Added Rationale section.
	<p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Removed ICD-10 codes B20, D86.0, D86.1, D86.2, D86.3, D86.81, D86.82, D86.83, D86.84, D86.85, D86.86, D86.87, D86.89, D86.9, E05.00, E05.01, E05.10, E05.11, E05.20, E05.21, E44.0, E44.1, E45, E64.3, E66.01, E66.09, E66.1, E66.8, E83.30, E83.31, E83.32, E83.39, E84.0, E84.19, E84.8, E84.9, E89.2, G40.001, G40.009, G40.011, G40.019, G40.101, G40.109, G40.111, G40.119, G40.201, G40.209, G40.211, G40.219, G40.301, G40.309, G40.401, G40.409, G40.411, G40.419, G40.501, G40.509, G40.801, G40.802, G40.811, G40.812, G40.813, G40.814, G40.821, G40.822, G40.823, G40.824, G40.89, G40.901, G40.909, G40.911, G40.919, G40.A01, G40.A09, G40.A11, G40.A19, G40.B01, G40.B09, G40.B11, G40.B19, K50.00, K50.018, K50.019, K50.10, K50.118, K50.119, K50.80, K50.818, K50.819, K50.90, K50.918, K50.919, K51.00, K51.018, K51.019, K51.20, K51.218, K51.219, K51.30, K51.318, K51.319, K51.80, K51.818, K51.819, K51.90, K51.918, K51.919, K73.9, K86.0, K86.1, K90.9, M62.81, M89.9, M94.9, N18.2, P71.0, P71.1, P71.2, P71.3, P71.4, P71.8, P71.9, R17, Z91.81</li> <li>▪ Added ICD-10 codes E20.0, E20.1, E20.8, E21.4, E83.52, K71.0, K71.10, K71.11, K71.2, K71.3, K71.4, K71.50, K71.51, K71.6, K71.7, K71.8, K72.10, K72.11, K74.0, K74.60, K74.69, K75.3, K75.4, K75.89, K76.0, K76.1, K76.2, K76.3, K76.4, K76.5, K76.7, K76.81, K76.89, K77, K83.0, K83.1, K83.2, K83.3, K83.4, K83.5, K83.8, K90.81, M80.011A-S, M80.012A-S, K80.021A-S, M80.022A-S, M80.031A-S, M80.032A-S, M80.041A-S, M80.042A-S, M80.051A-S, M80.052A-S, M80.061A-S, M80.062A-S, M80.071A-S, M80.072A-S, M80.08XA-S, M80.811A-S, M80.812A-S, M80.821A-S, M80.822A-S, M80.831A-S, M80.832A-S, M80.841A-S, M80.842A-S, M80.851A-S, M80.952A-S, M80.861A-S, M80.862A-S, M80.871A-S, M80.872A-S, M80.88XA-S, M83.0, M83.1, M83.2, M83.3, M83.4, M83.5, M83.8, M85.811, M85.812, M85.821, M85.822, M85.831, M85.832, M85.841, M85.842, M85.851, M85.852, M85.861, M85.862, M85.871, M85.872, M85.88, N18.3, N18.4, N18.5, N18.6, Q78.0, Q78.2, Z59.3, Z79.52, Z79.899</li> </ul>
	Updated References section.
	Added Appendix section.
10-01-2016	<p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Added ICD-10 code effective 10-01-2016: K90.49</li> <li>▪ Termed ICD-10 code effective 09-30-2016: K90.4</li> </ul>

<b>REVISIONS</b>	
01-25-2017	Updated Description section.
	Updated Rationale section.
	In Coding section: <ul style="list-style-type: none"> <li>▪ Added ICD-10 code: K90.9.</li> </ul>
	Updated References section.
02-15-2018	Updated Description section.
	Updated Rationale section.
	In Coding section: <ul style="list-style-type: none"> <li>▪ Removed ICD-9 codes.</li> </ul>
	Updated References section.
03-28-2018	Updated Appendix section.
	In Coding section: <ul style="list-style-type: none"> <li>▪ Added CPT code: 0038U.</li> </ul>
10-01-2018	In Coding section: <ul style="list-style-type: none"> <li>▪ Added ICD-10 codes: K83.01, K83.09.</li> <li>▪ Removed ICD-10 code: K83.0.</li> </ul>
02-01-2019	Updated Description section.
	Updated Rationale section.
	Updated References section.
	Removed Appendix section.
10-01-2020	In Coding Section: Added ICD-10: K74.00, K74.01, K74.02, N18.31, N18.32 Removed ICD-10: K74.0, N18.3
04-19-2021	Updated Description section.
	Updated Rationale section.
	Updated References section.
2-25-2022	Changed Title to Testing Serum Vitamin D Levels
	Updated Description Section
	Updated Policy Section <ul style="list-style-type: none"> <li>▪ Section A4 changed to read Cirrhosis "and" chronic liver disease</li> <li>▪ Section A6 changed to read "systemic" corticosteroids</li> <li>▪ Section A15 changed to read osteosclerosis "and" osteopetrosis</li> <li>▪ Section C word "is" was changed to "are"</li> </ul>
	Updated Rationale Section
	In the Coding section <ul style="list-style-type: none"> <li>▪ Changed ICD-10 codes to code ranges</li> </ul>
	Updated References Section
	Updated References Section
01-24-2023	Updated Description Section
	Updated Rationale Section
	Updated References Section
01-23-2024	Updated Description Section
	Updated Rationale Section
	Updated Coding Section <ul style="list-style-type: none"> <li>▪ Removed ICD-10 Codes</li> </ul>
	Updated References Section

**REFERENCES**

1. Shapses SA, Manson JE. Vitamin D and prevention of cardiovascular disease and diabetes: why the evidence falls short. *JAMA*. Jun 22 2011; 305(24): 2565-6. PMID 21693745
2. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Food and Nutrition Board. *Dietary Reference Intakes for Calcium and Vitamin D*. Washington, DC: National Academies Press; 2011.
3. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int*. Oct 2022; 33(10): 2049-2102. PMID 35478046
4. Herrick KA, Storandt RJ, Afful J, et al. Vitamin D status in the United States, 2011-2014. *Am J Clin Nutr*. Jul 01 2019; 110(1): 150-157. PMID 31076739
5. Yetley EA. Assessing the vitamin D status of the US population. *Am J Clin Nutr*. Aug 2008; 88(2): 558S-564S. PMID 18689402
6. Cranney A, Horsley T, O'Donnell S, et al. *Effectiveness and Safety of Vitamin D in Relation to Bone Health (Evidence Reports/Technology Assessments No. 158)*. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
7. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. *N Engl J Med*. Feb 16 2006; 354(7): 669-83. PMID 16481635
8. Holvik K, Ahmed LA, Forsmo S, et al. Low serum levels of 25-hydroxyvitamin D predict hip fracture in the elderly: a NOREPOS study. *J Clin Endocrinol Metab*. Aug 2013; 98(8): 3341-50. PMID 23678033
9. Cauley JA, Lacroix AZ, Wu L, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. *Ann Intern Med*. Aug 19 2008; 149(4): 242-50. PMID 18711154
10. Mithal A, Wahl DA, Bonjour JP, et al. Global vitamin D status and determinants of hypovitaminosis D. *Osteoporos Int*. Nov 2009; 20(11): 1807-20. PMID 19543765
11. Cauley JA, Parimi N, Ensrud KE, et al. Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men. *J Bone Miner Res*. Mar 2010; 25(3): 545-53. PMID 19775201
12. Looker AC, Mussolino ME. Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. *J Bone Miner Res*. Jan 2008; 23(1): 143-50. PMID 17907920
13. Jia X, Aucott LS, McNeill G. Nutritional status and subsequent all-cause mortality in men and women aged 75 years or over living in the community. *Br J Nutr*. Sep 2007; 98(3): 593-9. PMID 17442130
14. Visser M, Deeg DJ, Puts MT, et al. Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. *Am J Clin Nutr*. Sep 2006; 84(3): 616-22; quiz 671-2. PMID 16960177
15. Theodoratou E, Tzoulaki I, Zgaga L, et al. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. *BMJ*. Apr 01 2014; 348: g2035. PMID 24690624
16. DEQAS (Vitamin D External Quality Assurance Scheme). n.d.; <http://www.deqas.org/>. Accessed October 20, 2023.
17. LeBlanc ES, Zakher B, Daeges M, et al. Screening for vitamin D deficiency: a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med*. Jan 20 2015; 162(2): 109-22. PMID 25419719
18. Ling Y, Xu F, Xia X, et al. Vitamin D supplementation reduces the risk of fall in the vitamin D deficient elderly: An updated meta-analysis. *Clin Nutr*. 2021;40(11):5531-5537. doi:10.1016/j.clnu.2021.09.031

19. Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. *Cochrane Database Syst Rev.* Apr 15 2009; (2): CD000227. PMID 19370554
20. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. *Arch Intern Med.* Mar 23 2009; 169(6): 551-61. PMID 19307517
21. Palmer SC, McGregor DO, Craig JC, et al. Vitamin D compounds for people with chronic kidney disease requiring dialysis. *Cochrane Database Syst Rev.* Oct 07 2009; (4): CD005633. PMID 19821349
22. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA.* May 11 2005; 293(18): 2257-64. PMID 15886381
23. Appel LJ, Michos ED, Mitchell CM, et al. The Effects of Four Doses of Vitamin D Supplements on Falls in Older Adults : A Response-Adaptive, Randomized Clinical Trial. *Ann Intern Med.* Feb 2021; 174(2): 145-156. PMID 33284677
24. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *JAMA.* May 12 2010; 303(18): 1815-22. PMID 20460620
25. Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. *J Clin Endocrinol Metab.* Jul 2011; 96(7): 1931-42. PMID 21677037
26. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and cardiometabolic outcomes. *Ann Intern Med.* Mar 02 2010; 152(5): 307-14. PMID 20194237
27. Chung M, Balk EM, Brendel M, et al. Vitamin D and calcium: a systematic review of health outcomes. *Evid Rep Technol Assess (Full Rep).* Aug 2009; (183): 1-420. PMID 20629479
28. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. *Circulation.* Jan 29 2008; 117(4): 503-11. PMID 18180395
29. Su C, Jin B, Xia H, et al. Association between Vitamin D and Risk of Stroke: A PRISMA-Compliant Systematic Review and Meta-Analysis. *Eur Neurol.* 2021; 84(6): 399-408. PMID 34325429
30. Fu J, Sun J, Zhang C. Vitamin D supplementation and risk of stroke: A meta-analysis of randomized controlled trials. *Front Neurol.* 2022; 13: 970111. PMID 36062009
31. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. *BMJ.* Jul 29 2010; 341: c3691. PMID 20671013
32. Keum N, Lee DH, Greenwood DC, et al. Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. *Ann Oncol.* May 01 2019; 30(5): 733-743. PMID 30796437
33. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of cancer in adults. *Cochrane Database Syst Rev.* Jun 23 2014; (6): CD007469. PMID 24953955
34. Ott SM, Chesnut CH. Calcitriol treatment is not effective in postmenopausal osteoporosis. *Ann Intern Med.* Feb 15 1989; 110(4): 267-74. PMID 2913914
35. Grady D, Halloran B, Cummings S, et al. 1,25-Dihydroxyvitamin D3 and muscle strength in the elderly: a randomized controlled trial. *J Clin Endocrinol Metab.* Nov 1991; 73(5): 1111-7. PMID 1939527

36. Komulainen M, Kröger H, Tuppurainen MT, et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial. *J Clin Endocrinol Metab.* Feb 1999; 84(2): 546-52. PMID 10022414
37. Gallagher JC, Fowler SE, Detter JR, et al. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. *J Clin Endocrinol Metab.* Aug 2001; 86(8): 3618-28. PMID 11502787
38. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ.* Mar 01 2003; 326(7387): 469. PMID 12609940
39. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. *N Engl J Med.* Feb 16 2006; 354(7): 684-96. PMID 16481636
40. Daly RM, Petrass N, Bass S, et al. The skeletal benefits of calcium- and vitamin D3-fortified milk are sustained in older men after withdrawal of supplementation: an 18-mo follow-up study. *Am J Clin Nutr.* Mar 2008; 87(3): 771-7. PMID 18326617
41. LaCroix AZ, Kotchen J, Anderson G, et al. Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. *J Gerontol A Biol Sci Med Sci.* May 2009; 64(5): 559-67. PMID 19221190
42. Bolton-Smith C, McMurdo ME, Paterson CR, et al. Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women. *J Bone Miner Res.* Apr 2007; 22(4): 509-19. PMID 17243866
43. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *Am J Clin Nutr.* Jun 2007; 85(6): 1586-91. PMID 17556697
44. Prince RL, Austin N, Devine A, et al. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. *Arch Intern Med.* Jan 14 2008; 168(1): 103-8. PMID 18195202
45. Janssen HC, Samson MM, Verhaar HJ. Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. *Aging Clin Exp Res.* Feb 2010; 22(1): 78-84. PMID 20305368
46. Brunner RL, Wactawski-Wende J, Caan BJ, et al. The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. *Nutr Cancer.* 2011; 63(6): 827-41. PMID 21774589
47. Avenell A, MacLennan GS, Jenkinson DJ, et al. Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial). *J Clin Endocrinol Metab.* Feb 2012; 97(2): 614-22. PMID 22112804
48. Glendenning P, Zhu K, Inderjeeth C, et al. Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial. *J Bone Miner Res.* Jan 2012; 27(1): 170-6. PMID 21956713
49. Larsen T, Mose FH, Bech JN, et al. Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. *Am J Hypertens.* Nov 2012; 25(11): 1215-22. PMID 22854639

50. Murdoch DR, Slow S, Chambers ST, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. *JAMA*. Oct 03 2012; 308(13): 1333-9. PMID 23032549
51. Wood AD, Secombes KR, Thies F, et al. Vitamin D3 supplementation has no effect on conventional cardiovascular risk factors: a parallel-group, double-blind, placebo-controlled RCT. *J Clin Endocrinol Metab*. Oct 2012; 97(10): 3557-68. PMID 22865902
52. Witham MD, Price RJ, Struthers AD, et al. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. *JAMA Intern Med*. Oct 14 2013; 173(18): 1672-9. PMID 23939263
53. Baron JA, Barry EL, Mott LA, et al. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. *N Engl J Med*. Oct 15 2015; 373(16): 1519-30. PMID 26465985
54. Jorde R, Sollid ST, Svartberg J, et al. Vitamin D 20,000 IU per Week for Five Years Does Not Prevent Progression From Prediabetes to Diabetes. *J Clin Endocrinol Metab*. Apr 2016; 101(4): 1647-55. PMID 26829443
55. Lappe J, Watson P, Travers-Gustafson D, et al. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. *JAMA*. Mar 28 2017; 317(12): 1234-1243. PMID 28350929
56. Scragg R, Khaw KT, Toop L, et al. Monthly High-Dose Vitamin D Supplementation and Cancer Risk: A Post Hoc Analysis of the Vitamin D Assessment Randomized Clinical Trial. *JAMA Oncol*. Nov 01 2018; 4(11): e182178. PMID 30027269
57. Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. *N Engl J Med*. Jan 03 2019; 380(1): 33-44. PMID 30415629
58. Liu M, Wang J, Sun X. A Meta-Analysis on Vitamin D Supplementation and Asthma Treatment. *Front Nutr*. 2022; 9: 860628. PMID 35873428
59. Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. *Lancet Respir Med*. Nov 2017; 5(11): 881-890. PMID 28986128
60. Williamson A, Martineau AR, Sheikh A, et al. Vitamin D for the management of asthma. *Cochrane Database Syst Rev*. Feb 06 2023; 2(2): CD011511. PMID 36744416
61. Martineau AR, Cates CJ, Urashima M, et al. Vitamin D for the management of asthma. *Cochrane Database Syst Rev*. Sep 05 2016; 9(9): CD011511. PMID 27595415
62. Luo J, Liu D, Liu CT. Can Vitamin D Supplementation in Addition to Asthma Controllers Improve Clinical Outcomes in Patients With Asthma?: A Meta-Analysis. *Medicine (Baltimore)*. Dec 2015; 94(50): e2185. PMID 26683927
63. Ramos-Martínez E, López-Vancell MR, Fernández de Córdoba-Aguirre JC, et al. Reduction of respiratory infections in asthma patients supplemented with vitamin D is related to increased serum IL-10 and IFN $\gamma$  levels and cathelicidin expression. *Cytokine*. Aug 2018; 108: 239-246. PMID 29402723
64. Jiang C, Yi R, Na H, Lin S. A randomized controlled study of Vitamin D3 supplementation on childhood asthma control. *Chongqing Medicine*. 2017;46(32):4505-7.
65. Jerzynska J, Stelmach W, Rychlik B, et al. The clinical effect of vitamin D supplementation combined with grass-specific sublingual immunotherapy in children with allergic rhinitis. *Allergy Asthma Proc*. 2016; 37(2): 105-14. PMID 26932169
66. Forno E, Bacharier LB, Phipatanakul W, et al. Effect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial. *JAMA*. Aug 25 2020; 324(8): 752-760. PMID 32840597



67. Ducharme FM, Jensen M, Mailhot G, et al. Impact of two oral doses of 100,000 IU of vitamin D 3 in preschoolers with viral-induced asthma: a pilot randomised controlled trial. *Trials*. Feb 18 2019; 20(1): 138. PMID 30777118
68. Camargo CA, Toop L, Sluyter J, et al. Effect of Monthly Vitamin D Supplementation on Preventing Exacerbations of Asthma or Chronic Obstructive Pulmonary Disease in Older Adults: Post Hoc Analysis of a Randomized Controlled Trial. *Nutrients*. Feb 06 2021; 13(2). PMID 33561963
69. Andújar-Espinosa R, Salinero-González L, Illán-Gómez F, et al. Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: the ACVID randomised clinical trial. *Thorax*. Feb 2021; 76(2): 126-133. PMID 33154023
70. Aglipay M, Birken C, Dai D, et al. High Dose Vitamin D for the Prevention of Wheezing in Preschoolers: A Secondary Analysis of a Randomized Clinical Trial. *J Paediatr Child Health*. 2019;24(S2):e27-e28.
71. Worth H, Stammen D, Keck E. Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate. *Am J Respir Crit Care Med*. Aug 1994; 150(2): 394-7. PMID 8049820
72. Majak P, Rychlik B, Stelmach I. The effect of oral steroids with and without vitamin D3 on early efficacy of immunotherapy in asthmatic children. *Clin Exp Allergy*. Dec 2009; 39(12): 1830-41. PMID 19817753
73. Urashima M, Segawa T, Okazaki M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. *Am J Clin Nutr*. May 2010; 91(5): 1255-60. PMID 20219962
74. Majak P, Olszowiec-Chlebna M, Smejda K, et al. Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection. *J Allergy Clin Immunol*. May 2011; 127(5): 1294-6. PMID 21315433
75. Lewis E, Fernandez C, Nella A, et al. Relationship of 25-hydroxyvitamin D and asthma control in children. *Ann Allergy Asthma Immunol*. Apr 2012; 108(4): 281-2. PMID 22469451
76. Baris S, Kiykim A, Ozen A, et al. Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite. *Allergy*. Feb 2014; 69(2): 246-53. PMID 24180595
77. Castro M, King TS, Kunselman SJ, et al. Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. *JAMA*. May 2014; 311(20): 2083-91. PMID 24838406
78. Yadav M, Mittal K. Effect of vitamin D supplementation on moderate to severe bronchial asthma. *Indian J Pediatr*. Jul 2014; 81(7): 650-4. PMID 24193954
79. de Groot JC, van Roon EN, Storm H, et al. Vitamin D reduces eosinophilic airway inflammation in nonatopic asthma. *J Allergy Clin Immunol*. Mar 2015; 135(3): 670-5.e3. PMID 25617224
80. Martineau AR, MacLaughlin BD, Hooper RL, et al. Double-blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with asthma (ViDiAs). *Thorax*. May 2015; 70(5): 451-7. PMID 25724847
81. Tachimoto H, Mezawa H, Segawa T, et al. Improved control of childhood asthma with low-dose, short-term vitamin D supplementation: a randomized, double-blind, placebo-controlled trial. *Allergy*. Jul 2016; 71(7): 1001-9. PMID 26841365
82. Jensen ME, Mailhot G, Alos N, et al. Vitamin D intervention in preschoolers with viral-induced asthma (DIVA): a pilot randomised controlled trial. *Trials*. Jul 26 2016; 17(1): 353. PMID 27456232

83. Kerley CP, Hutchinson K, Cormican L, et al. Vitamin D3 for uncontrolled childhood asthma: A pilot study. *Pediatr Allergy Immunol*. Jun 2016; 27(4): 404-12. PMID 26845753
84. Musharraf MU, Sandhu GA, Mumtaz MU, Rashid MF. Role of vitamin D in prevention of acute exacerbation of bronchial asthma in adults. *J Postgrad Med Inst*. 2017;31:3103. doi: 10.1002/rmv.1909
85. Dodamani MH, Muthu V, Thakur R, et al. A randomised trial of vitamin D in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. *Mycoses*. Apr 2019; 62(4): 320-327. PMID 30561849
86. Shabana MA, Esawy MM, Ismail NA, et al. Predictive role of IL-17A/IL-10 ratio in persistent asthmatic patients on vitamin D supplement. *Immunobiology*. Nov 2019; 224(6): 721-727. PMID 31570180
87. Jat KR, Goel N, Gupta N, et al. Efficacy of vitamin D supplementation in asthmatic children with vitamin D deficiency: A randomized controlled trial (ESDAC trial). *Pediatr Allergy Immunol*. Apr 2021; 32(3): 479-488. PMID 33207014
88. Thakur C, Kumar J, Kumar P, et al. Vitamin-D supplementation as an adjunct to standard treatment of asthma in children: A randomized controlled trial (ViDASTA Trial). *Pediatr Pulmonol*. Jun 2021; 56(6): 1427-1433. PMID 33522698
89. Litonjua AA, Carey VJ, Laranjo N, et al. Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial. *JAMA*. Jan 26 2016; 315(4): 362-70. PMID 26813209
90. Palacios C, Kostiuik LK, Peña-Rosas JP. Vitamin D supplementation for women during pregnancy. *Cochrane Database Syst Rev*. Jul 26 2019; 7(7): CD008873. PMID 31348529
91. Brooke OG, Brown IR, Bone CD, et al. Vitamin D supplements in pregnant Asian women: effects on calcium status and fetal growth. *British Medical Journal* 1980;1:751-754.
92. Delvin EE, Salle BL, Glorieux FH, et al. Vitamin D supplementation during pregnancy: effect on neonatal calcium homeostasis. *J Pediatr*. Aug 1986; 109(2): 328-34. PMID 3488384
93. Mallet E, Gügi B, Brunelle P, et al. Vitamin D supplementation in pregnancy: a controlled trial of two methods. *Obstet Gynecol*. Sep 1986; 68(3): 300-4. PMID 3755517
94. Marya RK, Rathee S, Dua V, et al. Effect of vitamin D supplementation during pregnancy on foetal growth. *Indian J Med Res*. Dec 1988; 88: 488-92. PMID 3243609
95. Kaur J, Marya RK, Rathee S, Lal H, Singh GP. Effect of pharmacological doses of vitamin D during pregnancy on placental protein status and birth weight. *Nutrition Research*. 1991;11(9):1077-1081.
96. Yu C, Newton L, Robinson S, Teoh TG, Sethi M. Vitamin D deficiency and supplementation in pregnant women of four ethnic groups. *Archives of Disease in Childhood. Fetal and Neonatal Edition*. 2008;93(Suppl 1):Fa68.
97. Roth DE, Al Mahmud A, Raqib R, et al. Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial. *Nutr J*. Apr 12 2013; 12: 47. PMID 23587190
98. Sabet Z, Ghazi AA, Tohidi M, Oladi B. Vitamin D supplementation in pregnant Iranian women: Effects on maternal and neonatal vitamin D and parathyroid hormone status. *Acta Endocrinologica*. 2012;8(1):59-66.
99. Asemi Z, Samimi M, Tabassi Z, et al. Vitamin D supplementation affects serum high-sensitivity C-reactive protein, insulin resistance, and biomarkers of oxidative stress in pregnant women. *J Nutr*. Sep 2013; 143(9): 1432-8. PMID 23884390

100. Grant CC, Stewart AW, Scragg R, et al. Vitamin D during pregnancy and infancy and infant serum 25-hydroxyvitamin D concentration. *Pediatrics*. Jan 2014; 133(1): e143-53. PMID 24344104
101. Tehrani HG, Mostajeran F, Banihashemi B. Effect of Vitamin D Supplementation on the Incidence of Gestational Diabetes. *Adv Biomed Res*. 2017; 6: 79. PMID 28808645
102. Mirghafourvand M, Mohammad-Alizadeh-Charandabi S, Mansouri A, Najafi M, Khodabande F. The effect of vitamin D and calcium plus vitamin D on sleep quality in pregnant women with leg cramps: A controlled randomized clinical trial. *Journal of Isfahan Medical School*. 2015;32(320):2444-2453.
103. Rodda CP, Benson JE, Vincent AJ, et al. Maternal vitamin D supplementation during pregnancy prevents vitamin D deficiency in the newborn: an open-label randomized controlled trial. *Clin Endocrinol (Oxf)*. Sep 2015; 83(3): 363-8. PMID 25727810
104. Sablok A, Batra A, Thariani K, et al. Supplementation of vitamin D in pregnancy and its correlation with fetomaternal outcome. *Clin Endocrinol (Oxf)*. Oct 2015; 83(4): 536-41. PMID 25683660
105. Singh J, Hariharan C, Bhaumik D. Role of vitamin D in reducing the risk of preterm labour. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*. 2015;1:86-93.
106. Khan F. A randomized controlled trial of oral vitamin D supplementation in pregnancy to improve maternal periodontal health and birth weight. *Journal of International Oral Health* 2016;8(6):657-65.
107. Cooper C, Harvey NC, Bishop NJ, et al. Maternal gestational vitamin D supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind, randomised placebo-controlled trial. *Lancet Diabetes Endocrinol*. May 2016; 4(5): 393-402. PMID 26944421
108. Naghshineh E, Sheikhalian S. Effect of vitamin D supplementation in the reduce risk of preeclampsia in nulliparous women. *Adv Biomed Res*. 2016; 5: 7. PMID 26962509
109. Shahgheibi S, Farhadifar F, Pouya B. The effect of vitamin D supplementation on gestational diabetes in high-risk women: Results from a randomized placebo-controlled trial. *J Res Med Sci*. 2016; 21: 2. PMID 27904548
110. Vaziri F, Dabbaghmanesh MH, Samsami A, et al. Vitamin D supplementation during pregnancy on infant anthropometric measurements and bone mass of mother-infant pairs: A randomized placebo clinical trial. *Early Hum Dev*. Dec 2016; 103: 61-68. PMID 27513714
111. Behjat Sasan S, Zandvakili F, Soufizadeh N, et al. The Effects of Vitamin D Supplement on Prevention of Recurrence of Preeclampsia in Pregnant Women with a History of Preeclampsia. *Obstet Gynecol Int*. 2017; 2017: 8249264. PMID 28912817
112. Samimi M, Kashi M, Foroozanfard F, et al. The effects of vitamin D plus calcium supplementation on metabolic profiles, biomarkers of inflammation, oxidative stress and pregnancy outcomes in pregnant women at risk for pre-eclampsia. *J Hum Nutr Diet*. Aug 2016; 29(4): 505-15. PMID 26467311
113. Pozuelo-Moyano B, Benito-León J, Mitchell AJ, et al. A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. *Neuroepidemiology*. 2013; 40(3): 147-53. PMID 23257784
114. James E, Dobson R, Kuhle J, et al. The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. *Mult Scler*. Oct 2013; 19(12): 1571-9. PMID 23698130

115. Jagannath VA, Fedorowicz Z, Asokan GV, et al. Vitamin D for the management of multiple sclerosis. *Cochrane Database Syst Rev.* Dec 08 2010; (12): CD008422. PMID 21154396
116. LeBlanc ES, Chou R, Pappas M. Screening for vitamin D deficiency. *Ann Intern Med.* May 19 2015; 162(10): 738. PMID 25984861
117. Newberry SJ, Chung M, Shekelle PG, et al. Vitamin D and Calcium: A Systematic Review of Health Outcomes (Update). Evidence Report/Technology Assessment No. 217. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
118. Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. *BMJ.* Apr 01 2014; 348: g1903. PMID 24690623
119. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. *Cochrane Database Syst Rev.* Jan 10 2014; (1): CD007470. PMID 24414552
120. Palmer SC, McGregor DO, Craig JC, et al. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. *Cochrane Database Syst Rev.* Oct 07 2009; (4): CD008175. PMID 19821446
121. ACOG Committee Opinion No. 495: Vitamin D: Screening and supplementation during pregnancy. *Obstet Gynecol.* Jul 2011; 118(1): 197-198. PMID 21691184
122. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* Jul 2011; 96(7): 1911-30. PMID 21646368
123. Krist AH, Davidson KW, Mangione CM, et al. Screening for Vitamin D Deficiency in Adults: US Preventive Services Task Force Recommendation Statement. *JAMA.* Apr 13 2021; 325(14): 1436-1442. PMID 33847711
124. Kahwati LC, LeBlanc E, Weber RP, et al. Screening for Vitamin D Deficiency in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* Apr 13 2021; 325(14): 1443-1463. PMID 33847712
125. Noridian Healthcare Solutions. Local Coverage Determination (LCD): Vitamin D Assay Testing (L36692). 2017; <https://med.noridianmedicare.com/documents/10546/6990981/Vitamin+D+Assay+Testing+LCD>. Accessed October 23, 2023.

## OTHER REFERENCES

1. Blue Cross and Blue Shield of Kansas Internal Medicine Liaison Committee, January 2010; August 2013; August 2014; February 2016; June 2017.
2. Blue Cross and Blue Shield of Kansas OB/GYN Liaison Committee, July 2015; January 2016; May 2017.
3. Blue Cross and Blue Shield of Kansas Family Practice Liaison Committee, July 2014.
4. Blue Cross and Blue Shield of Kansas Family Medicine and Internal Medicine Liaison Committees, CB February 2016.